Kanvas looks amazing! They’re systematically deciphering microbiomes and developing clinical-stage interventions to improve patient outcomes in oncology and beyond. Very impressive! I’m also especially interested in their approach to maternal environmental enteric dysfunction (EED), which apparently affects 150M people!
Ever since the genomics revolution revealed how reliant the human organism is on its microscopic microbial cohabitants, the microbiome has been medicine’s most elusive frontier, promising better health if only we could untangle the trillions of interactions that influence nearly every facet of our physiology. But until now, effective medicines that harness the microbiome have been rare. Because of the diversity of microbial species and the complexity of host-to-microbe interactions, as well as the lack of a reliable, easily manufactured drug modality (the package that delivers a medicine’s therapeutic effect), the microbiome has been hard to treat, despite its importance to functions like immune response. Microbiome science has disappointed patients, doctors, founders, and investors.
That’s why DCVC is so excited about the cascade of recent developments at Kanvas Biosciences, which is moving the field beyond descriptive profiling of the microbiome to translating comprehensive biochemical insights into clinically useful products. In the past few weeks, the Princeton-based spatial biology company has kicked off a Phase 1 clinical trial for its first drug candidate, secured significant new backing from the Gates Foundation (closing a $48 million Series A financing, bringing Kanvas’s total funding to $78 million), and bolstered its scientific leadership by adding one of the most respected names in bioengineering to its board.
Clinical milestone
The most significant milestone in Kanvas’s evolution is the dosing of the first patients in a Phase I clinical trial for KAN-4. This live biotherapeutic product (LBP), resembling an ordinary pill, treats the colitis that many cancer patients develop after receiving immune checkpoint inhibitors (ICIs), allowing them to remain on the life-saving therapy longer.





